Monas OFT5 mg

Monas OFT 5 mg Sodium is a selective and orally active leukotriene receptor antagonist (LTRA) indicated for the prevention and long-term management of respiratory allergic conditions in adults and children. It is prescribed across a wide age range — from infants as young as 6 months to adults — in various formulations tailored to each age group.

Prophylaxis and Chronic Treatment of Asthma

Monas OFT 5 mg Sodium is indicated for the prophylaxis and long-term chronic treatment of asthma in adults and pediatric patients from 6 months of age and older. It is used to:

• Prevent daytime and night-time asthma symptoms
• Reduce the frequency of asthma exacerbations
• Decrease airway inflammation and bronchoconstriction associated with allergic and non-allergic asthma
• Reduce the need for short-acting beta-agonist (SABA) rescue therapy
• Allow for gradual reduction of inhaled corticosteroid (ICS) doses under medical supervision in patients who are well-controlled
• Improve lung function (FEV1, morning and evening peak expiratory flow)

Monas OFT 5 mg is particularly beneficial in patients with concurrent asthma and allergic rhinitis (the "one airway, one disease" concept), where it can address both conditions simultaneously with once-daily oral therapy. It is also particularly effective in patients with aspirin-exacerbated respiratory disease (AERD / aspirin-sensitive asthma), where leukotriene overproduction is a key pathophysiological mechanism.

Important: Monas OFT 5 mg is not a rescue medication. It should not be used to relieve acute bronchospasm or status asthmaticus. Patients must always have appropriate quick-relief (rescue) bronchodilator therapy available.

Acute Prevention of Exercise-Induced Bronchoconstriction (EIB)

Monas OFT 5 mg Sodium is indicated for the acute prevention of exercise-induced bronchoconstriction (EIB) in patients aged 6 years and older. A single dose taken at least 2 hours before exercise significantly attenuates the bronchoconstrictor response triggered by physical exertion. Patients already taking Monas OFT 5 mg once daily for asthma or allergic rhinitis should not take an additional dose for EIB prevention. Monas OFT 5 mg should not be used as the sole or primary treatment for exercise-induced bronchoconstriction — it should be part of an overall asthma management plan.

Relief of Symptoms of Seasonal Allergic Rhinitis (SAR)

Monas OFT 5 mg Sodium is indicated for the relief of symptoms of seasonal allergic rhinitis (hay fever) in adults and pediatric patients aged 2 years and older. It reduces the following symptoms caused by pollen, mold spores, and other seasonal outdoor allergens:

• Nasal congestion and blockage
• Rhinorrhea (runny nose) with clear discharge
• Sneezing and nasal pruritus (itching)
• Ocular symptoms — itchy, watery, red eyes (allergic conjunctivitis)

Relief of Symptoms of Perennial Allergic Rhinitis (PAR)

Monas OFT 5 mg Sodium is also indicated for the relief of symptoms of perennial allergic rhinitis (year-round rhinitis) in adults and pediatric patients aged 6 months and older. Perennial rhinitis is triggered by year-round indoor allergens such as house dust mites, cockroach antigens, pet dander, and indoor mold — conditions highly prevalent in Bangladesh's humid tropical climate.

Leukotriene Receptor Antagonists (LTRAs) / Antiasthmatic Drugs

Monas OFT 5 mg Sodium is a selective, competitive, and orally active antagonist of the cysteinyl leukotriene-1 (CysLT1) receptor. It belongs to the class of drugs known as leukotriene receptor antagonists (LTRAs) — also called antileukotrienes — and represents an entirely different mechanistic approach to asthma and rhinitis management compared to corticosteroids, beta-agonists, and antihistamines.

The Leukotriene Pathway — Background

Understanding Monas OFT 5 mg's mechanism requires understanding the role of leukotrienes in allergic inflammation:

1. Exposure to allergens (pollen, dust mites, mold, animal dander) activates mast cells and eosinophils in the airways and nasal mucosa.
2. These activated cells metabolize cell membrane arachidonic acid through the 5-lipoxygenase (5-LOX) pathway, generating cysteinyl leukotrienes (CysLTs) — specifically LTC4, LTD4, and LTE4.
3. These potent lipid mediators bind to the CysLT1 receptor, which is expressed on airway smooth muscle cells, mucosal goblet cells, eosinophils, macrophages, and dendritic cells.
4. CysLT1 receptor activation produces multiple downstream effects that collectively drive asthma and allergic rhinitis:
   • Airway smooth muscle contraction — bronchoconstriction (leukotrienes are 1,000 times more potent bronchoconstrictors than histamine)
   • Airway edema and increased vascular permeability — mucosal swelling causing congestion
   • Mucus hypersecretion — increased goblet cell output and airway plugging
   • Eosinophilic airway inflammation — recruitment and activation of eosinophils perpetuating chronic inflammation
   • Dendritic cell activation — amplification of the Th2 adaptive immune response
   • Nasal congestion — particularly during the late-phase allergic response

Mechanism of Action

Monas OFT 5 mg competitively and selectively binds to the CysLT1 receptor with high affinity and potency, blocking the receptor's activation by all three cysteinyl leukotrienes (LTC4, LTD4, LTE4). By occupying the CysLT1 receptor, Monas OFT 5 mg:

• Prevents leukotriene-mediated bronchoconstriction and airway smooth muscle contraction
• Reduces leukotriene-mediated airway edema and mucosal swelling
• Decreases mucus secretion into the airways
• Attenuates the recruitment and survival of eosinophils in both the airway and nasal mucosa
• Reduces exercise-induced bronchoconstriction — since exercise triggers leukotriene release as a key mechanism of EIB
• Reduces nasal congestion and inflammatory changes in allergic rhinitis

Crucially, Monas OFT 5 mg acts at a complementary inflammatory pathway to antihistamines (which target H1 histamine receptors) and corticosteroids (which broadly suppress all inflammatory mediators). This allows Monas OFT 5 mg to be combined with these agents for additive clinical benefit, particularly in patients with comorbid asthma and rhinitis.

Pharmacokinetics

• Absorption: Monas OFT 5 mg is rapidly absorbed following oral administration. The mean oral bioavailability is approximately 64% for the 10 mg film-coated tablet. Peak plasma concentrations (C_max) are achieved in approximately 3 to 4 hours after administration in adults. Neither the rate nor extent of absorption is significantly affected by a standard meal — Monas OFT 5 mg may be taken with or without food at any time of day, though once-daily evening administration is recommended for asthma (aligned with peak nocturnal asthma symptoms).
• Distribution: Highly protein-bound — approximately 99% bound to plasma proteins, primarily albumin. Volume of distribution is approximately 8–11 L, indicating distribution primarily in plasma rather than tissues.
• Metabolism: Extensively metabolized in the liver, predominantly by CYP3A4 and CYP2C8 (minor contributions from CYP2C9). The metabolites are pharmacologically inactive at therapeutic concentrations. Monas OFT 5 mg does not itself significantly inhibit or induce major CYP enzymes at therapeutic doses.
• Half-life: Approximately 2.7 to 5.5 hours in healthy young adults; slightly longer in the elderly (approximately 6 hours). Despite this relatively short plasma half-life, the once-daily regimen provides 24-hour clinical efficacy — due in part to the irreversible-like binding to the CysLT1 receptor and the sustained pharmacodynamic effect.
• Elimination: Primarily biliary — approximately 86% of the dose is recovered in the feces (indicating predominantly hepatic/biliary excretion of metabolites). Less than 0.2% is recovered in the urine. This almost entirely non-renal elimination means no dose adjustment is needed for renal impairment.

Film-Coated Tablets (10 mg — Adults and Adolescents ≥15 Years)

• Monas OFT 5 mg 10 mg film-coated tablets may be taken with or without food — food does not significantly affect absorption or bioavailability.
• Swallow the tablet whole with a full glass of water.
• For asthma management, take in the evening before bedtime to provide maximum protection during overnight hours when asthma is typically most active.
• For allergic rhinitis without asthma, the tablet may be taken at any convenient time of day.
• Take at the same time each day to maintain consistent drug levels and clinical effect.

Chewable Tablets (4 mg and 5 mg — Children)

• Chew the tablet thoroughly before swallowing — do not swallow whole.
• May be given with or without food.
• The 5 mg chewable tablet is approved for children aged 6 to 14 years; the 4 mg chewable tablet is for children aged 2 to 5 years.
• Ensure the child chews the tablet fully before swallowing to enable complete dissolution and absorption.
• Take in the evening for asthma management.

Orally Disintegrating (Flash/ODT) Tablets (4 mg and 5 mg)

• Place the tablet on the tongue — it will dissolve rapidly without water (within seconds to minutes).
• Do not push the tablet through the blister packaging foil — carefully peel the foil back to remove the tablet and place immediately on the tongue.
• No water is needed, making this formulation ideal for young children who cannot chew or swallow tablets, and for patients with swallowing difficulties.
• Can be taken with or without food.

Oral Granules (4 mg per 3.5 g sachet — Infants and Young Children 6 Months to 5 Years)

• Open the sachet just before use. Do not store opened sachets — administer the entire contents immediately.
• The granules can be administered in the following ways:
  • Placed directly on the tongue and swallowed
  • Mixed with one teaspoon (approximately 5 ml) of cold or room-temperature water
  • Mixed with one teaspoon of soft food at room temperature — suitable foods include apple sauce, carrots, rice, or ice cream
• Do not mix the granules with juice, milk, formula, or warm/hot food or liquid, as this may affect drug stability.
• If mixed with food or water, administer immediately (within 15 minutes) — do not store the mixture for later use.
• Administer once daily, preferably in the evening for asthma-related use.

For Exercise-Induced Bronchoconstriction Prevention

• Take the age-appropriate dose at least 2 hours before exercise.
• Do not take more than one dose within a 24-hour period.
• Patients who are already taking Monas OFT 5 mg daily for asthma or allergic rhinitis should not take an additional dose before exercise.

Monas OFT 5 mg has a favorable drug interaction profile. At recommended clinical doses, Monas OFT 5 mg does not significantly affect the pharmacokinetics of other commonly co-prescribed medications. However, certain interactions require clinical awareness:

No Clinically Significant Interactions Established

In dedicated drug interaction studies and in extensive clinical trial populations, Monas OFT 5 mg at its recommended clinical dose was administered concurrently with the following drugs without producing clinically important pharmacokinetic changes in either direction:

• Theophylline — no significant effect on theophylline kinetics; no dose adjustment needed
• Prednisone and Prednisolone — no interaction; Monas OFT 5 mg may allow dose reduction of inhaled or oral corticosteroids under physician supervision, but cannot substitute for them
• Oral Contraceptives — norethindrone 1 mg / ethinyl estradiol 35 mcg combination was not affected; no impact on contraceptive efficacy
• Terfenadine — no interaction at recommended doses
• Digoxin — no clinically significant interaction
• Warfarin — no significant change in anticoagulant effect or pharmacokinetics; no routine INR monitoring change is required specifically for Monas OFT 5 mg
• Thyroid hormones, sedative hypnotics, NSAIDs, benzodiazepines, decongestants — no evidence of clinically adverse pharmacokinetic interactions in extensive clinical trial use

CYP3A4 and CYP2C8 Enzyme Inducers — Reduced Monas OFT 5 mg Levels

Monas OFT 5 mg is metabolized primarily by the hepatic enzymes CYP3A4 and CYP2C8. Drugs that potently induce these enzymes can significantly accelerate Monas OFT 5 mg metabolism, reducing its plasma concentrations and potentially its therapeutic efficacy:

• Phenobarbital: A potent hepatic enzyme inducer that decreased the AUC of Monas OFT 5 mg by approximately 40% following a single 10 mg oral dose. Although no dose adjustment for Monas OFT 5 mg is formally recommended, this interaction may reduce clinical efficacy — asthma control should be monitored if phenobarbital is co-prescribed.
• Rifampin (Rifampicin): A potent inducer of CYP3A4 and CYP2C8; expected to reduce Monas OFT 5 mg plasma levels similarly to phenobarbital. Monitor asthma and rhinitis control during concurrent rifampin therapy.
• Carbamazepine, Phenytoin: Other hepatic enzyme inducers that may potentially reduce Monas OFT 5 mg levels through similar mechanisms. Appropriate clinical monitoring of asthma control is advisable.

Recommendation: It is reasonable to employ appropriate clinical monitoring when potent CYP450 enzyme inducers (particularly phenobarbital or rifampin) are co-administered with Monas OFT 5 mg. If asthma or rhinitis control deteriorates, consider increasing the monitoring frequency and reviewing alternative or add-on therapies.

Gemfibrozil (CYP2C8 Inhibitor)

Gemfibrozil, a lipid-lowering agent and potent CYP2C8 inhibitor, has been shown to increase Monas OFT 5 mg plasma AUC by approximately 4.5-fold through inhibition of Monas OFT 5 mg's primary metabolic pathway. While this interaction does not appear to be associated with serious safety concerns at standard doses (Monas OFT 5 mg has a wide therapeutic index), clinicians should be aware of potentially higher drug exposure and monitor for any dose-dependent adverse effects.

Additive Benefit with Other Antiasthmatic/Antiallergic Agents

Monas OFT 5 mg is designed to be used in combination with other antiasthmatic and antiallergic medications as part of a stepwise management approach. Established and clinically beneficial combinations include:

• Inhaled corticosteroids (ICS): Monas OFT 5 mg has complementary anti-inflammatory mechanisms to ICS — together they provide additive control of eosinophilic inflammation and broader symptom management. Combined ICS + Monas OFT 5 mg therapy can achieve better asthma control than ICS monotherapy in some patients.
• Short-acting beta-agonists (SABAs) and long-acting beta-agonists (LABAs): Monas OFT 5 mg does not interact pharmacokinetically with bronchodilators and can be safely co-administered.
• Antihistamines (H1 antagonists): Monas OFT 5 mg and antihistamines target different aspects of the allergic cascade (leukotrienes vs. histamine). Combination therapy provides additive symptom relief in allergic rhinitis and, for some patients, superior control to either agent alone — particularly for nasal congestion (which antihistamines address poorly).
• Intranasal corticosteroids: Monas OFT 5 mg can be used alongside intranasal steroids for more complete rhinitis symptom control.

Monas OFT 5 mg Sodium is generally well tolerated across all age groups. Most adverse effects are mild to moderate in severity. The following adverse events are classified by frequency:

Common Side Effects (Affecting 1 in 100 to 1 in 10 Patients)

• Headache — most frequently reported adverse effect across clinical trials
• Gastrointestinal discomfort — abdominal pain, dyspepsia
• Nausea and vomiting
• Diarrhea
• Upper respiratory tract infection
• Skin reactions — rash, urticaria, pruritus
• Fever

Uncommon Side Effects (Affecting 1 in 1,000 to 1 in 100 Patients)

• Neuropsychiatric effects:
  • Anxiety
  • Depression
  • Irritability
  • Akathisia (restlessness, unease, inability to keep still)
  • Abnormal behavior
  • Sleep disorders — insomnia, abnormal dreams
  • Drowsiness and dizziness
• Asthenia (weakness and fatigue)
• Malaise
• Arthralgia (joint pain)
• Myalgia (muscle pain)
• Oedema (fluid retention and swelling)
• Dry mouth
• Haemorrhage (bleeding tendency)
• Seizures (convulsions)
• Abnormal skin sensations (paraesthesia)

Rare Side Effects (Affecting Fewer than 1 in 1,000 Patients) — Some Serious

• Angioedema — swelling of the face, lips, tongue, or throat; requires immediate medical attention
• Suicidal ideation and behavior — rare but serious neuropsychiatric effect; requires immediate discontinuation and medical evaluation (see Black Box Warning below)
• Hallucinations and disorientation
• Memory impairment and concentration difficulties
• Tremor
• Palpitations
• Hepatic disorders — elevated liver enzymes, cholestatic hepatitis; rare and usually reversible upon discontinuation
• Pulmonary eosinophilia
• Eosinophilic Granulomatosis with Polyangiitis (EGPA) — formerly known as Churg-Strauss syndrome; an extremely rare systemic vasculitis associated with eosinophilia. Has been reported in patients receiving Monas OFT 5 mg, usually in the context of reducing oral corticosteroid doses, suggesting unmasking of pre-existing EGPA rather than causation. If EGPA is suspected (eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, peripheral neuropathy), Monas OFT 5 mg should be discontinued and specialist evaluation undertaken.
• Erythema nodosum — painful reddish-purple nodules on the shins; rare skin manifestation

Black Box Warning — Neuropsychiatric Events (FDA, 2020)

In March 2020, the US FDA added a black box warning to the Monas OFT 5 mg prescribing information regarding serious neuropsychiatric adverse events. These include:

• Agitation and aggressive behavior
• Anxiety, depression, and mood changes
• Disorientation and confusion
• Dream abnormalities and insomnia
• Hallucinations
• Irritability and restlessness
• Memory impairment and attention deficit
• Obsessive-compulsive symptoms
• Suicidal ideation and behavior — including completed suicide
• Somnambulism (sleepwalking)
• Tremor

These neuropsychiatric effects have been reported in both adults and pediatric patients. The benefits and risks should be carefully weighed before prescribing Monas OFT 5 mg, particularly in patients with a history of anxiety, depression, or psychiatric disorders. Patients and caregivers should be informed of these risks and instructed to contact a physician immediately if any behavioral or mood changes occur during therapy. Monas OFT 5 mg should be discontinued if neuropsychiatric events develop.

Pregnancy

Monas OFT 5 mg crosses the placenta following oral dosing — this has been confirmed in animal studies (rats and rabbits). At doses exceeding the maximum recommended human dose, Monas OFT 5 mg has not been shown to be teratogenic or to cause reproductive toxicity in animal studies. However, as animal studies are not always predictive of human outcomes, there are no adequate and well-controlled studies in pregnant women. The safety of Monas OFT 5 mg during human pregnancy has not been fully established.

Monas OFT 5 mg should be used during pregnancy only if clearly needed — when the potential benefit to the mother justifies any theoretical risk to the fetus. Physicians should consider the risk of untreated or undertreated asthma during pregnancy (which is associated with increased maternal and fetal complications including preterm birth, low birth weight, and preeclampsia) against the theoretical risk of Monas OFT 5 mg. Where possible, well-established asthma medications with longer human safety records (particularly inhaled corticosteroids) should be preferred during pregnancy.

Post-marketing surveillance studies and pregnancy registries have not consistently identified an increased risk of major congenital malformations with first-trimester Monas OFT 5 mg exposure, but data remain limited.

Lactation

It is not known whether Monas OFT 5 mg is excreted into human breast milk. Since many lipophilic drugs are excreted in human milk, and given Monas OFT 5 mg's high plasma protein binding (99%), some transfer to breast milk is expected. However, because of the minimal renal excretion and predominantly hepatic/biliary elimination of Monas OFT 5 mg, the estimated infant exposure via breastfeeding would likely be low.

Caution should be exercised when Monas OFT 5 mg is administered to a nursing mother. The decision to continue breastfeeding while taking Monas OFT 5 mg should be made by weighing the significant benefits of breastfeeding for both infant and mother against any theoretical risk to the infant, in consultation with the treating physician.

Fertility

Animal studies with Monas OFT 5 mg did not demonstrate any effects on fertility. No human data on fertility effects are available, but no concerns have been identified.

Not a Rescue Medication — No Role in Acute Asthma

Monas OFT 5 mg is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. It does not have bronchodilator properties and will not relieve acute airflow obstruction. Patients should be explicitly counseled to:

• Always have appropriate quick-relief (rescue) medication available — typically a short-acting beta-agonist (SABA) such as salbutamol
• Seek immediate medical attention if their rescue bronchodilator provides insufficient relief or more frequent use is required
• Continue taking Monas OFT 5 mg during acute exacerbations, as it does not worsen asthma and may be continued alongside short-term intensification of asthma therapy

Do Not Substitute for Corticosteroids

While Monas OFT 5 mg may allow gradual reduction of the inhaled corticosteroid dose under medical supervision in some patients who achieve good asthma control, Monas OFT 5 mg must not be abruptly substituted for inhaled or oral corticosteroids. Abrupt corticosteroid withdrawal can precipitate severe asthma exacerbations. Any reduction in corticosteroid dose must be supervised and stepwise, with regular monitoring of asthma control.

Neuropsychiatric Events — Patient Counseling Essential

Given the FDA's 2020 Black Box Warning for serious neuropsychiatric events (see Side Effects section), all patients and their caregivers must receive comprehensive counseling before initiating Monas OFT 5 mg:

• Explain the range of possible neuropsychiatric effects — from behavioral changes and sleep disturbances to suicidal ideation
• Advise patients and caregivers to contact their physician immediately if they experience mood changes, behavioral disturbances, or signs of depression
• Weigh the benefit-risk ratio carefully in patients with a personal or family history of psychiatric disorders
• Monas OFT 5 mg should be discontinued if neuropsychiatric effects develop — effects are typically reversible upon discontinuation
• The restriction on use specifically in patients whose asthma is not adequately controlled by other agents helps minimize unnecessary exposure to this risk

Not for Exercise-Induced Bronchoconstriction Alone

Monas OFT 5 mg should not be used as the sole or primary treatment for exercise-induced bronchoconstriction. In patients with underlying asthma, comprehensive asthma management (including inhaled corticosteroids where indicated) is the primary therapeutic strategy. EIB prevention is an adjunctive benefit of Monas OFT 5 mg therapy, not an indication for its use in isolation.

Aspirin-Sensitive Asthma

Patients with known aspirin sensitivity and NSAID-triggered bronchospasm should continue to strictly avoid aspirin and all non-selective NSAIDs while taking Monas OFT 5 mg. Although Monas OFT 5 mg effectively improves airway function in aspirin-sensitive asthmatic patients (by blocking the leukotriene component of the aspirin-triggered response), it does not completely block the bronchoconstrictor response to aspirin or NSAIDs — it has not been shown to fully truncate the aspirin-induced bronchoconstriction in these patients. Accidental aspirin or NSAID exposure remains dangerous in aspirin-sensitive patients taking Monas OFT 5 mg.

Eosinophilia and Churg-Strauss Syndrome (EGPA)

Rare cases of eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) have been reported in patients receiving Monas OFT 5 mg — typically in the context of reducing systemic corticosteroid therapy. While a causal relationship with Monas OFT 5 mg has not been definitively established (it appears more likely that these cases represent unmasking of pre-existing vasculitis as corticosteroids are withdrawn), physicians should monitor patients for eosinophilia, vasculitic rash, cardiac complications, peripheral neuropathy, and worsening pulmonary symptoms. If EGPA is suspected, Monas OFT 5 mg should be discontinued and specialist evaluation sought urgently.

Driving and Machinery

Drowsiness and dizziness have been reported with Monas OFT 5 mg. Patients should assess their individual response before driving or operating heavy machinery. However, in clinical studies, psychomotor performance has not been significantly impaired at therapeutic doses.

Monas OFT 5 mg Sodium has a wide therapeutic index and serious toxicity from overdose is uncommon. The following is known from reported overdose cases:

• In the majority of overdose reports, no adverse experiences were observed.
• Where symptoms were reported, the most frequently occurring adverse effects were consistent with the established safety profile of Monas OFT 5 mg and included:
  • Abdominal pain
  • Somnolence (drowsiness)
  • Thirst
  • Headache
  • Vomiting
  • Psychomotor hyperactivity (restlessness, agitation, hyperkinesia)
• These symptoms generally resolved spontaneously without specific treatment.

Management of Overdose

• There is no specific antidote for Monas OFT 5 mg overdose.
• Management is symptomatic and supportive:
  • Remove unabsorbed drug from the gastrointestinal tract if indicated (activated charcoal if presented within 1 hour of ingestion and patient is conscious with intact airway)
  • Institute clinical monitoring — vital signs, level of consciousness, neurological status
  • Supportive therapy as required for specific symptoms
• It is not known whether Monas OFT 5 mg is dialyzable by peritoneal dialysis or hemodialysis, though its high protein binding (99%) suggests it is unlikely to be significantly removed by either method.

In the event of suspected Monas OFT 5 mg overdose, contact a poison control center or seek emergency medical care immediately.

• Store all Monas OFT 5 mg Sodium formulations below 30°C, in a cool, dry place protected from direct light and moisture.
• Keep all formulations out of the reach of children.
• Do not use any formulation after the expiry date printed on the packaging or label.
• Film-coated tablets and chewable tablets: Store in original blister packaging to protect from humidity and light. Do not remove tablets from the blister until immediately before administration.
• Orally disintegrating (ODT/flash) tablets: These are moisture-sensitive. Peel back the foil gently — do not push the tablet through the foil. Store in the original blister pack away from moisture.
• Oral granules (sachets): Store below 30°C in original sealed sachets. Open sachets only immediately before use — do not store opened sachets. Once opened, administer immediately (or within 15 minutes if mixed with food).
• Do not store Monas OFT 5 mg in a bathroom medicine cabinet where high humidity is common.
• Do not freeze any Monas OFT 5 mg formulation.
• Store all formulations away from heat sources and out of direct sunlight.

Pediatric Patients

The safety and efficacy of Monas OFT 5 mg have been established through adequate and well-controlled clinical studies in pediatric patients with asthma from 6 months to 14 years of age. The safety and efficacy profiles in this age group are comparable to those seen in adults. Key pediatric considerations:

• 6 months to 5 years: Oral granules (4 mg sachet) are the recommended formulation for this age group. The granules provide flexible administration options (directly in the mouth, or mixed with a small amount of cold water or room-temperature soft food).
• 2 to 5 years: The 4 mg chewable tablet is also suitable for children aged 2 years and above who can chew safely.
• 6 to 14 years: The 5 mg chewable, dispersible, or standard tablet is recommended. Orally disintegrating tablets (ODT/flash tablets) are particularly convenient for children who have difficulty swallowing.
• The neuropsychiatric adverse effects (see Side Effects) have been reported in pediatric patients. Careful monitoring of behavior and mood — especially in children with underlying psychiatric conditions — is important. Parents should be counseled to report any behavioral changes promptly.
• No evidence of adverse effects on growth or puberty was identified in controlled pediatric clinical studies of 1-year duration, though no long-term data beyond 1 year exist specifically for these endpoints.

Elderly Patients

The pharmacokinetic profile and oral bioavailability of Monas OFT 5 mg 10 mg are similar in elderly and younger adult patients. The plasma half-life is slightly longer in the elderly (approximately 6 hours vs. 3–5 hours in younger adults), but this modest difference has no clinically meaningful consequences. No dosage adjustment is required in elderly patients.

Elderly patients should be monitored for neuropsychiatric effects at the same level of vigilance as younger patients, as this population may be more susceptible to CNS adverse events from medications generally.

Patients with Hepatic Impairment

Since Monas OFT 5 mg is extensively metabolized in the liver, hepatic function can influence drug exposure. In clinical pharmacokinetic studies:

• Mild to moderate hepatic insufficiency: No dosage adjustment is required — the increase in Monas OFT 5 mg AUC was not considered clinically significant.
• Severe hepatic insufficiency: Patients have not been formally studied. Use with caution in severe hepatic impairment; clinical monitoring is advisable. Dose adjustment may be required based on clinical response and tolerability.

Patients with Renal Insufficiency

Since Monas OFT 5 mg and its metabolites are excreted almost entirely via biliary/fecal routes (less than 0.2% in urine), no dosage adjustment is recommended in patients with any degree of renal insufficiency, including severe renal failure or patients on dialysis. Renal function does not significantly affect Monas OFT 5 mg pharmacokinetics.